Table 2 Summary of studies reporting SLN procedures for cutaneous squamous cell carcinoma.
Author, year | # SCC cases | Location | SLN results and histological methods | Adjuvant Treatment | Disease Recurrence |
|---|---|---|---|---|---|
Stadelmann, 1997 [36] | 1 | Extremity | 1/1 (100%), H&E | LND | LR (n = 1, +SLN) |
Weisberg, 2000 [37] | 1 | Head | 0/1 (0%), H&E and IHC | XRT | none |
Altinyollar, 2002 [23] | 20 | Head | 3/18 (17%), H&E | LND | N/A |
Reschly, 2003 [10] | 9 | Head, Truncal/Extremity | 4/9 (44%), H&E and IHC | LND (n = 3), XRT (n = 1) | LR (n = 1, +SLN), DR (n = 1, +SLN) |
Michl, 2003 [24] | 9 | Head, Truncal/Extremity | 2/9 (22%), H&E and IHC | LND + CTX/XRT (n = 2) | DR (n = 1, +SLN) |
Eastman, 2004 [25] | 6 | Extremity | 4/6 (67%). H&E and IHC | N/A | N/A |
Ozcelik, 2004 [38] | 1 | Extremity | 0/1 (0%), H&E | none | none |
Wagner, 2004 [26] | 12 | Head, Truncal/Extremity | 2/12 (17%), H&E | XRT (n = 2) | none |
Hatta, 2005 [34] | 4 | Extremity | 0/4 (0%), H&E and IHC | N/A | N/A |
Perez-Naranjo, 2005 [39] | 1 | Extremity | 0/1 (0%), N/A | none | none |
Nouri, 2006 [27] | 15 | Head | 1/15 (6.7%), H&E and IHC | LND (n = 4) | none |
Mullen, 2006 [9] | 14 | Truncal/Extremity | 0/14 (0%), H&E + IHC | none | LR (n = 2, -SLN) NR (n = 1, -SLN) |
Sahn, 2007 [29] | 9 | Head, Truncal/Extremity | 0/9 (0%), H&E and some IHC | XRT (n = 3) | NR (n = 1, -SLN) DR (n = 1, -SLN) |
Renzi, 2007 [30] | 22 | Head, Truncal/Extremity | 1/22 (5%), H&E and IHC | LND (n = 1) | DR (n = 1, +SLN) |
Kwon, 2010 | 6 | Head, Truncal/Extremity | 0/6 (0%), H&E and some IHC. | none | LR (n = 1, -SLN) DR (n = 1, -SLN) |